Inspection Details
The United States Food and Drug Administration (US FDA) conducted an inspection at Unit-VI, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited. The inspection took place from August 24 to August 28, 2026. The facility is located at E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh.
Inspection Outcome
The inspection concluded with three observations, which are described as procedural in nature. The company will respond to the US FDA within the stipulated timeline.
Company Commitment and Compliance
The Company stated its commitment to maintaining robust quality and compliance standards across its manufacturing facilities. The Company will keep the Stock Exchanges informed of any further developments as required under applicable regulations.
Filing Details
Document dated: August 28, 2026
Filed by: B. Adi Reddy, Company Secretary
Regulatory reference: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Addressed to: National Stock Exchange of India Limited (Scrip Code: AUROPHARMA) and BSE Limited (Scrip Code: 524804)